Endocrine Abstracts

Objectives: Bone metastases in breast cancer are typically osteolytic but can rarely be osteoblastic. While malignancy-related hypercalcemia is well-known, malignancy-related hypocalcemia is rare and often multifactorial.

Case presentation: We present a case of a 48-year-old woman with metastatic breast cancer who developed severe hypocalcemia due to a combination of expanding osteoblastic bone metastases and hypopara - thyroidism after total thyroidectomy. Despite oral and intravenous calcium supplementation, adequate calcium levels were not achieved until the patient responded to systemic therapy with Trastuzumab Deruxtecan (T-DXd), a HER2-directed antibody-drug conjugate.

Conclusion: This case underscores the challenges in finding the cause of and managing hypocalcemia in patients with complex oncological histories and emphasizes the need for close calcium monitoring in patients with bone metastases, particularly those with additional risk factors such as hypoparathyroidism or treatment with anti-resorptive drugs.

References: 1. Harbeck N, Penault-Llorca F, Cortes J, et al. Breast cancer. Nat Rev Dis Primers. 2019;5(1):67. doi: 10.1038/s41572-019-0122-z 2. Kozlow W, Guise TA. Breast cancer metastasis to bone: mechanisms of osteolysis and implications for therapy. J Mammary Gland Biol Neoplasia. 2005;10(2):169–180. doi: 10.1007/s10911-005-5399-8 3. Zeng W, Swee DS. Severe and refractory hypocalcaemia secondary to osteoblastic bone metastases in bladder signet ring carcinoma: a case report and literature review. Medicine (Baltimore). 2022;101(26):e29731. doi: 10.1097/MD.0000000000029731 4. McBride A, Trifilio S, Baxter N, et al. Managing tumor lysis syndrome in the Era of novel cancer therapies. J Adv Pract Oncol. 2017;8(7):705–720. doi: 10.6004/jadpro.2017.8.7.4 5. Yerram P, Kansagra S, Abdelghany O. Incidence of hypocalcemia in patients receiving denosumab for prevention of skeletal-related events in bone metastasis. J Oncol Pharm Pract. 2017;23(3):179–184. doi: 10.1177/1078155216628325 6. Dadana S, Gundepalli S, Kondapalli A. Severe refractory hypocalcemia caused by Denosumab. Cureus. 2023;15(6):e39866. doi: 10.7759/cureus.39866 7. Stopeck AT, Fizazi K, Body JJ, et al. Safety of long-term denosumab therapy: results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancer. Support Care Cancer. 2016;24(1):447–455. doi: 10.1007/s00520-015-2904-5 8. Ikesue H, Tsuji T, Hata K, et al. Time course of calcium concentrations and risk factors for hypocalcemia in patients receiving denosumab for the treatment of bone metastases from cancer. Ann Pharmacother. 2014;48(9):1159–1165. doi: 10.1177/1060028014539919 9. Body JJ, Bone HG, de Boer RH, et al. Hypocalcaemia in patients with metastatic bone disease treated with denosumab. Eur J Cancer. 2015;51(13): 1812–1821. doi: 10.1016/j.ejca.2015.05.016 10. Modi S, Jacot W, Yamashita T, et al. Trastuzumab Deruxtecan in Previously treated HER2-low advanced breast cancer. N Engl J Med. 2022;387(1):9–20. doi: 10.1056/NEJMoa2203690 11. Bergkamp FJ, van Berkel AM, van der Linden PW, et al. Unexpected prolonged extreme hypocalcaemia and an inadequate PTH response in a patient with metastatic breast carcinoma. Neth J Med. 2003;61(11):371–375. 12. Kassi E, Kapsali I, Kokkinos M, et al. Treatment of severe hypocalcaemia due to osteoblastic metastases in a patient with post-thyroidectomy hypoparathyroidism with 153Sm-EDTMP. BMJ Case Rep. 2017;2017:bcr2017219354. doi: 10.1136/bcr-2017-219354

Keywords: Breast cancer, hypocalcemia, hypoparathyroidism, osteoblastic metastases